Bringing the fundamentals into focus…
Back to Allogene Therapeutics, Inc.
How Allogene Therapeutics, Inc. stacks up
ALLO · against 403 other Healthcare companies of similar size
Profitability
4/ 100
Near the bottom of its peers.
Ranked #390 of 404 · scores higher than 2% of peers
Bars: peers in each 10-point band of the profitability score42 peers with a profitability score of 0–9, including ALLO · Click a bar to see the companies
Why profitability scores 4?
Weighted metrics compared with all Healthcare companies.Mainly because of its operating margin, return on assets and return on invested capital, which are weaker than most Healthcare peers.
- a thinner operating margin: weaker than 97% of peers. Operating margin: -3886.1% vs peer median 7.1%
- a lower return on assets: weaker than 86% of peers. Return on assets: -30.1% vs peer median 1.7%
- a lower return on invested capital: weaker than 85% of peers. Return on invested capital: -35.8% vs peer median 4.7%
Metric by metric
Position: dot = ALLO, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ALLO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 373 reported | -35.8% | 0.8% | 19% | 33% | |
| Operating marginHigher is better · 376 reported | -3886.1% | 3.4% | 3% | 33% | |
| Return on assetsHigher is better · 402 reported | -30.1% | 0.4% | 17% | 33% | |
| Return on equityHigher is better · 381 reported | -42.4% | -0.3% | 19% | Context only | |
| Gross marginHigher is better · 422 reported | 0.0% | 37.8% | 5% | Context only |
Ranking by profitability score
Top 5 and the companies ranked around ALLO| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 595M USD | 99 | 97 | |
| 1 | 433M USD | 99 | 81 | |
| 1 | 578M USD | 99 | 73 | |
| 1 | 609M USD | 99 | 91 | |
| 5 | 4.4B CNY (≈$611M) | 98 | 77 | |
| 383 | 215M USD | 5 | 34 | |
| 383 | 469M USD | 5 | 45 | |
| 383 | 549M USD | 5 | 30 | |
| 390 | 551M USD | 4 | 20 | |
| 390 | 387M USD | 4 | 49 | |
| 390 | 530M USD | 4 | 23 | |
| 390 | 216M USD | 4 | 44 | |
| 390 | 453M USD | 4 | 6 | |
| 395 | 4.5B HKD (≈$579M) | 3 | 54 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score